NO318210B1 - Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav. - Google Patents

Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav. Download PDF

Info

Publication number
NO318210B1
NO318210B1 NO19933394A NO933394A NO318210B1 NO 318210 B1 NO318210 B1 NO 318210B1 NO 19933394 A NO19933394 A NO 19933394A NO 933394 A NO933394 A NO 933394A NO 318210 B1 NO318210 B1 NO 318210B1
Authority
NO
Norway
Prior art keywords
amino acid
human
ser
antibody
ige
Prior art date
Application number
NO19933394A
Other languages
English (en)
Norwegian (no)
Other versions
NO933394D0 (no
NO933394L (no
Inventor
Frank Kolbinger
Jose William Saldanha
Norman Hardman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220228A external-priority patent/GB9220228D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO933394D0 publication Critical patent/NO933394D0/no
Publication of NO933394L publication Critical patent/NO933394L/no
Publication of NO318210B1 publication Critical patent/NO318210B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19933394A 1992-09-24 1993-09-23 Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav. NO318210B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220228A GB9220228D0 (en) 1992-09-24 1992-09-24 Reshaped monoclonal antibodies against an immunologlobulin isotype
US95280292A 1992-09-25 1992-09-25

Publications (3)

Publication Number Publication Date
NO933394D0 NO933394D0 (no) 1993-09-23
NO933394L NO933394L (no) 1994-03-25
NO318210B1 true NO318210B1 (no) 2005-02-21

Family

ID=26301683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19933394A NO318210B1 (no) 1992-09-24 1993-09-23 Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.

Country Status (18)

Country Link
EP (2) EP1452542A3 (he)
JP (2) JP3636737B2 (he)
KR (1) KR100298608B1 (he)
CN (2) CN1078250C (he)
AT (1) ATE264388T1 (he)
AU (1) AU675449B2 (he)
CA (1) CA2106719C (he)
CY (1) CY2583B2 (he)
DE (1) DE69333484T2 (he)
DK (1) DK0589840T3 (he)
ES (1) ES2219640T3 (he)
FI (2) FI114550B (he)
HK (1) HK1056182A1 (he)
IL (2) IL107049A (he)
MX (1) MX9305920A (he)
NO (1) NO318210B1 (he)
NZ (1) NZ248743A (he)
PT (1) PT589840E (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU7156996A (en) * 1995-09-13 1997-04-01 Genentech Inc. Methods for treatment of interstitial cystitis
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1056471A4 (en) * 1998-01-29 2001-05-30 Tanox Inc TREATMENT OF ATOPIC DERMATITIS USING IgE ANTAGONISTS
BRPI0316092B8 (pt) * 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
CN1829806A (zh) * 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法
AU2004315197B2 (en) * 2004-02-02 2009-06-04 Tanox, Inc. Identification of novel IgE epitopes
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407392B2 (en) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5104604A (en) * 1989-10-05 1992-04-14 Dexter Electronic Materials Div. Of Dexter Corp. Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトIgEに対するモノクローナル抗体
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.

Also Published As

Publication number Publication date
ATE264388T1 (de) 2004-04-15
FI934145A0 (fi) 1993-09-22
DE69333484D1 (de) 2004-05-19
EP0589840A1 (en) 1994-03-30
ES2219640T3 (es) 2004-12-01
IL107049A0 (en) 1993-12-28
EP1452542A2 (en) 2004-09-01
IL107049A (he) 2006-07-05
CN1088986A (zh) 1994-07-06
KR100298608B1 (ko) 2001-11-22
AU675449B2 (en) 1997-02-06
JPH06225788A (ja) 1994-08-16
JP3636737B2 (ja) 2005-04-06
CN1428352A (zh) 2003-07-09
CN1078250C (zh) 2002-01-23
FI114550B (fi) 2004-11-15
FI115838B (fi) 2005-07-29
FI934145A (fi) 1994-03-25
CA2106719A1 (en) 1994-03-25
DE69333484T2 (de) 2005-03-24
IL173988A0 (en) 2006-07-05
MX9305920A (es) 1994-05-31
JP3718214B2 (ja) 2005-11-24
CA2106719C (en) 2006-03-28
KR940006602A (ko) 1994-04-25
EP1452542A3 (en) 2007-05-02
AU4748893A (en) 1994-03-31
CY2583B2 (en) 2009-11-04
FI20040696A (fi) 2004-05-19
NO933394D0 (no) 1993-09-23
EP0589840B1 (en) 2004-04-14
CN1254487C (zh) 2006-05-03
NO933394L (no) 1994-03-25
HK1056182A1 (en) 2004-02-06
NZ248743A (en) 1995-04-27
JP2004357712A (ja) 2004-12-24
PT589840E (pt) 2004-08-31
DK0589840T3 (da) 2004-07-26

Similar Documents

Publication Publication Date Title
US6072035A (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
JP3238049B2 (ja) マウス抗体可変部ドメインの免疫原性を減弱させた修飾免疫グロブリンの取得方法およびそれらを含有する組成物
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
AU706584B2 (en) Immunoglobulin variants
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JPH08507680A (ja) 組換え抗vla4抗体分子
NO334808B1 (no) CDR-podet antistoffmolekyl med spesifisitet for human TNF-alfa, forbindelse inneholdende antistoffmolekylet, DNA, klonings- eller ekspresjonsvektor, E.coli ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet, terapeutisk eller diagnostisk preparat, samt anvendelse av antistoffmolekylet
NO318210B1 (no) Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
JP2004536605A (ja) インターロイキン1β抗体
CN107531797A (zh) 凝血酶抗体、其抗原结合片段及医药用途
CN107949570A (zh) 多特异性结合蛋白
WO2018034597A1 (ru) Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
TW201725216A (zh) Pcsk9抗體、其抗原結合片段及其醫藥用途
WO2003093319A1 (en) Novel humanized anti-vap-1 monoclonal antibody
RU2807484C2 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и его фармацевтическое применение
JP6848016B2 (ja) 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
TW202409093A (zh) 融合蛋白

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees